Send us a text In this episode of All Things Amyloid, we hear from Dr. Giada Bianchi, hematologist at the Amyloidosis Program at Brigham & Women’s Hospital and Dana-Farber Cancer Institute. Adapted from her video, hear about the relationship between AL amyloidosis and multiple myeloma. While both AL amyloidosis and multiple myeloma are plasma cell disorders and share similar patient care treatments, they diverge in pathogenic mechanisms. It’s important to note that approximately 10-15% of...
All content for All Things Amyloid is the property of Mackenzie's Mission and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text In this episode of All Things Amyloid, we hear from Dr. Giada Bianchi, hematologist at the Amyloidosis Program at Brigham & Women’s Hospital and Dana-Farber Cancer Institute. Adapted from her video, hear about the relationship between AL amyloidosis and multiple myeloma. While both AL amyloidosis and multiple myeloma are plasma cell disorders and share similar patient care treatments, they diverge in pathogenic mechanisms. It’s important to note that approximately 10-15% of...
Send us a text When you have an incurable disease that has treatments available, like amyloidosis, unfortunately it does not necessarily mean there is a cure. Treatments can be effective in getting the disease under control and reducing side effects, but patients are continually monitored to ensure the disease doesn’t relapse. And if at some point the disease reactivates, emotions can come alive. In today’s episode we’ll be talking about relapsing and what patients may go through when that ha...
All Things Amyloid
Send us a text In this episode of All Things Amyloid, we hear from Dr. Giada Bianchi, hematologist at the Amyloidosis Program at Brigham & Women’s Hospital and Dana-Farber Cancer Institute. Adapted from her video, hear about the relationship between AL amyloidosis and multiple myeloma. While both AL amyloidosis and multiple myeloma are plasma cell disorders and share similar patient care treatments, they diverge in pathogenic mechanisms. It’s important to note that approximately 10-15% of...
